These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8289584)

  • 41. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zinc potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced dopamine depletion in caudate nucleus of mice brain.
    Hussain S; Ali SF
    Neurosci Lett; 2002 Dec; 335(1):25-8. PubMed ID: 12457734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice.
    Bourque M; Morissette M; Al Sweidi S; Caruso D; Melcangi RC; Di Paolo T
    Neuroendocrinology; 2016; 103(3-4):300-14. PubMed ID: 26227546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Joniec I; Ciesielska A; Kurkowska-Jastrzebska I; Przybylkowski A; Czlonkowska A; Czlonkowski A
    Brain Res; 2009 Mar; 1261():7-19. PubMed ID: 19401171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A; Fascetti F; Corsini GU; Piccardi MP
    Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.
    Arpin S; Lagrue E; Bodard S; Chalon S; Castelnau P
    Metab Brain Dis; 2009 Sep; 24(3):453-61. PubMed ID: 19789969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice.
    Grandbois M; Morissette M; Callier S; Di Paolo T
    Neuroreport; 2000 Feb; 11(2):343-6. PubMed ID: 10674483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Singh A; Verma P; Balaji G; Samantaray S; Mohanakumar KP
    Neurochem Int; 2016 Oct; 99():221-232. PubMed ID: 27395789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Dluzen D; Jain R; Liu B
    J Neurochem; 1994 Jan; 62(1):94-101. PubMed ID: 8263548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
    Grünblatt E; Mandel S; Maor G; Youdim MB
    J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
    Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
    Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of electroconvulsive shock on dopamine-1 and dopamine-2 receptor ligand binding activity in MPTP-treated mice.
    Sershen H; Wolinsky T; Douyon R; Hashim A; Wiener HL; Lajtha A; Coons EE; Serby M
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):58-63. PubMed ID: 7580173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Richardson JR; Caudle WM; Guillot TS; Watson JL; Nakamaru-Ogiso E; Seo BB; Sherer TB; Greenamyre JT; Yagi T; Matsuno-Yagi A; Miller GW
    Toxicol Sci; 2007 Jan; 95(1):196-204. PubMed ID: 17038483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
    Adeyemo OM; Youdim MB; Markey SP; Markey CJ; Pollard HB
    Eur J Pharmacol; 1993 Aug; 240(2-3):185-93. PubMed ID: 8243537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
    Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.